^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) + CC-115 (mTOR inhibitor, DNA PK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
598P - A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Published date:
09/13/2021
Excerpt:
The combination of Enza and CC-115 was safe and without PK interactions. Pts with PTEN deletion/mutation or any PI3K pathway alterations had an improved PSA response and longer median time on treatment, suggesting that dual AR and PI3K inhibition in pts with PI3K pathway alterations may lead to improved outcomes
Trial ID:
